Introduction: Co-transmission is the phenomenon where a single neuron releases two or more chemical messengers—classical neurotransmitters, neuropeptides, or ATP—affecting synaptic transmission and neuromodulation. For B. Pharm students, understanding co-transmission is essential for pharmacology, drug design and therapeutic strategies, since co-release alters receptor targets, synaptic plasticity and drug responses. Key concepts include co-release versus co-transmission, vesicle types (small clear vesicles vs dense-core vesicles), vesicular transporters (VGLUT, VMAT, VAChT, VGAT), and examples such as dopamine–glutamate and GABA–glycine co-release. This topic links molecular mechanisms to clinical implications in neuropsychiatric and pain treatments. Now let’s test your knowledge with 30 MCQs on this topic.
Q1. What does “co-transmission” primarily describe in neuroscience?
- The release of a single neurotransmitter only
- Simultaneous release of multiple chemical messengers from one neuron
- Electrical coupling between two neurons
- Long-term potentiation at excitatory synapses
Correct Answer: Simultaneous release of multiple chemical messengers from one neuron
Q2. Which term specifically refers to release of different transmitters from the same synaptic vesicle?
- Co-transmission
- Co-release
- Autocrine signaling
- Paracrine signaling
Correct Answer: Co-release
Q3. Which vesicle type typically contains neuropeptides rather than classical small-molecule neurotransmitters?
- Small clear synaptic vesicles
- Dense-core vesicles
- Endosomes
- Exosomes
Correct Answer: Dense-core vesicles
Q4. Which vesicular transporter is responsible for loading glutamate into synaptic vesicles?
- VMAT
- VGLUT
- VGAT
- VAChT
Correct Answer: VGLUT
Q5. Co-transmission involving a classical neurotransmitter and a neuropeptide commonly shows which release difference?
- Neuropeptides are released at lower frequency than classical transmitters
- Neuropeptides are released only after high-frequency stimulation
- Classical transmitters require more Ca2+ than peptides for release
- Peptides are immediately reuptaken like monoamines
Correct Answer: Neuropeptides are released only after high-frequency stimulation
Q6. Which of the following is an example of co-transmission reported in midbrain neurons?
- Dopamine and glutamate co-release
- Acetylcholine and glycine co-release
- Serotonin and ATP co-release in cerebellum
- Norepinephrine and GABA co-release in retina
Correct Answer: Dopamine and glutamate co-release
Q7. Vesicular synergy describes which phenomenon?
- Competition between vesicles for docking sites
- One transmitter’s vesicular uptake enhancing uptake of another transmitter
- Vesicle fusion preventing subsequent release
- Loss of vesicle proton gradient due to reuptake
Correct Answer: One transmitter’s vesicular uptake enhancing uptake of another transmitter
Q8. Which transporter loads monoamines into synaptic vesicles?
- VGLUT1
- VGAT
- VMAT2
- EAAT2
Correct Answer: VMAT2
Q9. Which experimental technique is commonly used to directly visualize co-localization of transmitters in terminals?
- Patch-clamp electrophysiology only
- Immunohistochemistry with confocal microscopy
- Behavioral assays
- Microdialysis without histology
Correct Answer: Immunohistochemistry with confocal microscopy
Q10. ATP often acts as a co-transmitter. Which receptor family mediates rapid ATP signaling?
- GABA-A receptors
- Ionotropic P2X receptors
- Metabotropic muscarinic receptors
- Tyrosine kinase receptors
Correct Answer: Ionotropic P2X receptors
Q11. In co-transmission, how do neuropeptides typically differ from small-molecule transmitters in termination of action?
- Neuropeptides are removed by high-affinity transporters
- Neuropeptides are degraded extracellularly by peptidases
- Neuropeptides are rapidly reuptaken like glutamate
- Neuropeptides are endocytosed by postsynaptic neurons
Correct Answer: Neuropeptides are degraded extracellularly by peptidases
Q12. Which pharmacological agent blocks vesicular monoamine transporters and affects co-transmission of monoamines?
- Reserpine
- Cocaine
- Bicuculline
Correct Answer: Reserpine
Q13. Co-transmission can alter drug responses because:
- Only one transmitter is ever pharmacologically active
- Multiple co-released messengers can target different receptor classes
- Co-transmission prevents receptor activation
- It makes synapses electrically silent
Correct Answer: Multiple co-released messengers can target different receptor classes
Q14. Which pair is a classic example of inhibitory co-release in the spinal cord?
- Glutamate and dopamine
- GABA and glycine
- Serotonin and acetylcholine
- ATP and substance P
Correct Answer: GABA and glycine
Q15. Which property of dense-core vesicles distinguishes their release compared to small clear vesicles?
- Dense-core vesicles release at active zones only
- Dense-core vesicle release is less dependent on intracellular Ca2+
- Dense-core vesicle release often requires higher-frequency stimulation and broader Ca2+ influx
- Dense-core vesicles contain only classical neurotransmitters
Correct Answer: Dense-core vesicle release often requires higher-frequency stimulation and broader Ca2+ influx
Q16. Which receptor type mediates fast ionotropic glutamatergic transmission often modulated by co-transmitters?
- Metabotropic GABA-B receptors
- NMDA and AMPA receptors
- Muscarinic acetylcholine receptors
- Dopamine D2 receptors
Correct Answer: NMDA and AMPA receptors
Q17. Which of the following best explains how co-transmission contributes to synaptic plasticity?
- Co-transmission makes synapses static and unchangeable
- Different co-released agents activate distinct signaling cascades that modulate receptor trafficking and gene expression
- Co-transmission reduces postsynaptic receptor sensitivity permanently
- Co-transmission solely increases vesicle recycling speed
Correct Answer: Different co-released agents activate distinct signaling cascades that modulate receptor trafficking and gene expression
Q18. Which technique can demonstrate functional co-release by measuring postsynaptic currents from identified receptors?
- Western blotting
- Patch-clamp electrophysiology with pharmacological blockers
- Genome sequencing
- Ultracentrifugation
Correct Answer: Patch-clamp electrophysiology with pharmacological blockers
Q19. Substance P is commonly co-released with which classical transmitter in nociceptive pathways?
- GABA
- Glutamate
- Glycine
- Acetylcholine
Correct Answer: Glutamate
Q20. Which statement about co-transmission and drug targeting is true?
- Drugs targeting one receptor type can fully predict therapeutic outcome without considering co-transmitters
- Co-transmission can create off-target effects via secondary receptor systems, affecting efficacy and side effects
- Co-transmission only matters in invertebrates
- Co-transmission prevents any pharmacological modulation
Correct Answer: Co-transmission can create off-target effects via secondary receptor systems, affecting efficacy and side effects
Q21. Which transporter is responsible for loading GABA into synaptic vesicles?
- VGLUT2
- VGAT (also called VIAAT)
- VAChT
- NET
Correct Answer: VGAT (also called VIAAT)
Q22. Which of the following is a likely consequence when a neuron co-releases an excitatory transmitter and a peptide neuromodulator?
- Immediate short-term excitation only, with no lasting change
- Fast postsynaptic excitation combined with slower modulatory effects that alter receptor sensitivity or gene expression
- Complete inhibition of synaptic transmission
- Peptide prevents any receptor binding
Correct Answer: Fast postsynaptic excitation combined with slower modulatory effects that alter receptor sensitivity or gene expression
Q23. Which molecule is NOT typically considered a classical neurotransmitter co-released with peptides?
- Glutamate
- Dopamine
- Neuropeptide Y
- GABA
Correct Answer: Neuropeptide Y
Q24. How does co-release of glutamate with dopamine in mesencephalic neurons influence signaling?
- It only inhibits postsynaptic targets
- It allows rapid excitatory signaling via glutamate and modulatory dopaminergic signaling over longer timescales
- It prevents dopamine synthesis
- It causes vesicles to shrink
Correct Answer: It allows rapid excitatory signaling via glutamate and modulatory dopaminergic signaling over longer timescales
Q25. Which pharmacological approach can help isolate peptide-mediated effects in co-transmission studies?
- Using selective antagonists for peptide receptors or inhibiting peptidases
- Blocking all ion channels nonspecifically
- Removing extracellular Ca2+ only
- Using electrical stimulation without blockers
Correct Answer: Using selective antagonists for peptide receptors or inhibiting peptidases
Q26. Which statement about vesicular proton gradient is relevant to co-transmission?
- Vesicular proton gradient has no role in transmitter uptake
- Proton gradient drives uptake of many transmitters via vesicular transporters, influencing co-packaging
- Proton gradient only affects peptide synthesis
- Proton gradient is irrelevant to VMAT function
Correct Answer: Proton gradient drives uptake of many transmitters via vesicular transporters, influencing co-packaging
Q27. Which clinical area might benefit from understanding co-transmission for better drug design?
- Neuropsychiatric disorders like depression and schizophrenia
- Only dermatological conditions
- Bone fracture healing exclusively
- Hair growth regulation only
Correct Answer: Neuropsychiatric disorders like depression and schizophrenia
Q28. Which evidence supports the existence of co-release rather than sequential release?
- Distinct postsynaptic effects that cannot occur simultaneously
- Immunogold electron microscopy showing two transmitters in the same vesicle
- Behavioral changes without synaptic recordings
- Absence of vesicular transporters
Correct Answer: Immunogold electron microscopy showing two transmitters in the same vesicle
Q29. Which is true regarding regulation of receptor responses during co-transmission?
- Activation of metabotropic receptors by a co-transmitter cannot influence ionotropic receptor function
- Metabotropic co-transmitters can modulate ionotropic receptor phosphorylation and trafficking
- Ionotropic receptors are immune to intracellular signaling changes
- Receptor regulation only occurs at the transcriptional level
Correct Answer: Metabotropic co-transmitters can modulate ionotropic receptor phosphorylation and trafficking
Q30. Which is a common method to pharmacologically separate co-released fast and slow signals in slice physiology?
- Apply receptor-specific antagonists for fast ionotropic receptors and separate blockers or peptidase inhibitors for slower modulatory pathways
- Use only tonic electrical stimulation
- Ignore postsynaptic responses and record only presynaptic potentials
- Apply broad-spectrum protease inhibitors only
Correct Answer: Apply receptor-specific antagonists for fast ionotropic receptors and separate blockers or peptidase inhibitors for slower modulatory pathways
I am a Registered Pharmacist under the Pharmacy Act, 1948, and the founder of PharmacyFreak.com. I hold a Bachelor of Pharmacy degree from Rungta College of Pharmaceutical Science and Research. With a strong academic foundation and practical knowledge, I am committed to providing accurate, easy-to-understand content to support pharmacy students and professionals. My aim is to make complex pharmaceutical concepts accessible and useful for real-world application.
Mail- Sachin@pharmacyfreak.com